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Pneumocystis jirovecii is a symbiotic respiratory fungus that presents in 2 clinical forms: pneumonia in immu-
nocompromised patients or colonization, defined by the presence of the organism without associated clinical
symptoms. Currently, diagnosis requires invasive bronchoscopy, which may not be available in some settings
and is inappropriate for detecting colonization in healthy individuals. Noninvasive diagnostic techniques and
molecular strain typing tools that can be used on these samples are critical for conducting studies to better un-
derstand transmission. We evaluated 2 real-time polymerase chain reaction (PCR) assays targeting dihydropter-
oate synthase and the major surface glycoprotein for detection in 77 oropharyngeal washes (OPWs) from 43
symptomatic human immunodeficiency virus-infected patients who underwent bronchoscopy. We also evalu-
ated the ability of a new microsatellite (MS) genotyping panel to strain type infections from these samples. Each
PCR used individually provided a high sensitivity (>80%) for detection of pneumonia but a modest specificity
(<70%). When used in combination, specificity was increased to 100% with a drop in sensitivity (74%). Concen-
tration of organisms by PCR in the OPW tended to be lower in colonized individuals compared with those with
pneumonia, but differences in concentration could not clearly define colonization in symptomatic individuals.
Oropharyngeal wash samples were genotyped using 6 MSs with≥4 alleles successfully genotyped in the majority
of colonized patients and≥5 alleles in patients with pneumonia. The MS profile was consistent over time within
patients with serial OPWs analyzed. Microsatellite genotyping on noninvasive samples may aid in studying the
molecular epidemiology of this pathogen without requiring invasive diagnostic techniques.
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Pneumocystis jirovecii is a symbiotic respiratory fungus that
maycausepneumonia (Pneumocystispneumonia [PcP]) in
immunocompromised patients [1–5]. Despite significant
reductions in cases of pneumonia due to the use ofP jirove-
cii prophylaxis in high-risk individuals, PcP remains a sig-
nificant opportunistic pneumonia [3, 5]. Among human
immunodeficiency virus (HIV)-infected patients who do
not receive combination antiretroviral therapy, PcP re-
mains a leading cause of death [6, 7]. Mortality rates
range from 10% to nearly 40% in those with severe pneu-
moniaandrespiratory failure [8–10].Inaddition,outbreaks
among other immunocompromised groups, such as
hematopoietic stemcell andsolidorgan transplantpatients,
can cause significant morbidity and mortality [11–14].
Because P jirovecii cannot be cultured, PcP is usually
diagnosed by direct examination of specimens collected
by induced sputum (IS) or bronchoscopy with broncho-
alveolar lavage (BAL). Induced sputum has been quite
variable in its sensitivity leaving invasive bronchoscopy
as the gold standard diagnostic procedure. However,
bronchoscopy is generally unavailable in resource-
limited settings such as in sub-Saharan Africa where the
majority of HIV-infected persons reside. Noninvasive
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methods with the potential for widespread applicability and ac-
cessibility have been sought to aid in the detection of P jirovecii
and diagnosis of PcP. Examination of oropharyngeal wash
(OPW) specimens paired with molecular techniques has been
studied using many different approaches [15–20]. The sensitiv-
ity of OPW for the diagnosis of PcP has exceeded 90% in some
cases [15]. However, no standardized protocol has been devel-
oped. One of the limitations of molecular techniques has been
that the specificity for PcP is less than 100% because colonized
individuals, defined as the molecular detection of fungal DNA
in respiratory specimens from asymptomatic humans, have rel-
atively low but detectable amounts of P jirovecii DNA [21].
The impact of colonized individuals on transmission of
P jirovecii is incompletely understood [22]. Pneumocystis can
be transmitted from a colonized animal to an immunocompro-
mised animal, which then becomes fatally ill with PcP. To
broadly study the role of colonization in the transmission of
P jirovecii in humans, we must be able to identify colonized
and infected individuals by collection of specimens in a nonin-
vasive fashion and apply molecular typing tools to these speci-
mens. In a recent study, we described a multilocus microsatellite
(MS) genotyping array to investigate the genetic epidemiology
of P jirovecii [1]. We identified 6 MSs that captured the majority
of global diversity. These neutrally evolving markers had a high
discriminatory index and significant heterogeneity. In addition,
we saw that many of the samples contained multiple genotypes
represented as multiple alleles seen at a given MS.
The goal of this study was 3-fold. First, we investigated the
use of real-time polymerase chain reaction (PCR) to diagnose
PcP and/or detect colonization in symptomatic individuals.
We did this by testing OPW samples from 43 HIV-infected in-
dividuals presenting with respiratory symptoms and radio-
graphs consistent with PcP who underwent IS and/or BAL for
diagnosis. For this study, the microscopy from the BAL or IS
acted as the gold standard reference test to which real-time
PCR was compared. Colonization was defined as PCR positivity
with negative microscopy by IS or BAL. We investigated the use
of 2 assays in combination and looked at the differences in
P jirovecii concentration between individuals to try to increase
specificity of diagnosis of pneumonia. Second, we determined
whether the MS genotyping tool we had previously studied in
IS and BAL samples was capable of determining genotypes
from noninvasive OPW samples. Last, we describe the dynam-
ics of genotypes identified in longitudinally collected OPWs
from the same individual, because variation in detected geno-
types may impact our understanding of transmission.
METHODS
Study Samples
We analyzed 77 OPW samples from 43 HIV-infected patients
admitted to San Francisco General Hospital with respiratory
symptoms and a chest radiograph consistent with PcP and
who underwent sputum induction and/or bronchoscopy. Pa-
tient characteristics are described in Supplementary Table 1.
Oropharyngeal wash specimens were collected at the time of
the initial PcP evaluation and continued throughout the hospi-
talization in a subset. Thus, each individual could contribute
more than 1 OPW collected serially. The range of the number
of samples per individual patient was 1–13 (median, 1; mean,
1.9). Oropharyngeal wash specimens were collected by having
the patient cough 5 times against a semiclosed mouth, followed
by gargling 10 mL of sterile 0.9% NaCl for 60 seconds, and then
spitting the OPW specimen in a sterile specimen cup. An equal
volume of dithiothreitol was then added, and the specimen was
mixed, stored at −80°C, and shipped to University of North
Carolina for PCR and MS analysis. Ethical approval for the col-
lection of OPW samples and accompanying clinical information
was granted by the University of California San Francisco Com-
mittee on Human Research. Approval for molecular analysis of
deidentified patient samples was provided by the Institutional
Review Board at University of North Carolina.
DNA Extraction
The two 15 mL conical tubes containing OPW samples were
spun at 2900 g for 5 minutes at 12°C in a Sorvall T 16R (Ther-
mo Scientific, Waltham, MA). The supernatant was removed
with a sterile pipette. Two hundred microliters of TE buffer
(pH 8.0) was added to one of the pellets and was mixed by pi-
petting. The buffer was then moved to the second pellet and
mixed again to resuspend all the recovered cells. DNA was ex-
tracted using QIAGEN DNA Mini kits (QIAGEN, Valencia,
CA).
Real-Time Polymerase Chain Reaction
Each sample was tested with 2 real-time PCR assays. A real-time
PCR assay targeting the gene encoding dihydropteroate syn-
thase (dhps) was conducted as previously described [23]. As a
positive control, we generated a plasmid by PCR amplification
of the dhps fragment using the real-time PCR primers and clon-
ing of the fragment into the pCR4-Topo plasmid using a TOPO
TA cloning kit (Life Technologies, Grand Island, NY). This
plasmid was used to generate a standard curve (ranging from
10 to 10 000 copies per microliter) that was run on all PCR
plates to allow quantification of the amount of P jirovecii in
the sample, because dhps is a single-copy gene. A real-time
PCR assay targeting the gene encoding the major surface glyco-
protein (MSG) was done using a previously published primer
set [24, 25]. For this assay, samples were amplified using
Roche FastStart Universal SYBR master mix, 800 nM of each
primer (JKK14/15), and 2 µL of extract DNA. Amplification
was completed as follows: 50°C for 2 minutes, 95°C for 10 min-
utes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 1
minute. Specificity of amplification was confirmed using a melt
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curve analysis (60°C–95°C at 0.05°C/second). A positive control
from a BAL sample was used. All PCRs contained an NTC and
were done on an ABI Viia7 (Life Technologies).
Microsatellite Analysis
Microsatellite analysis was carried out on all samples that were
positive by both real-time PCR assays and that also contained
≥2 copies of P jirovecii per microliter of extracted DNA presum-
ing that these would represent PcP infections. In addition, sam-
ples that tested positive by a single real-time PCR assay were
also genotyped presuming these would represent colonized in-
dividuals because we were blinded to IS and BAL results. Gen-
otyping of 6 MSs (MS1, MS3, MS5, MS6, MS7, MS8) was
carried out as previously described [1]. All samples were sized
by capillary electrophoresis at Eton Bioscience (Durham, NC)
using an ABI 3730XL Genetic Analyzer. Peak calling was
done using Peak Scanner 2 (Life Technologies); for loci with
multiple peaks in a single specimen, additional peaks were
only considered if they reached at least 33% of the largest
peak in the sample, based on our previous work [1].
Statistical Analysis
All statistical analysis and figures were done with GraphPad
Prism, version 6.05 (GraphPad Software, La Jolla, CA).
RESULTS
Description of Patient Characteristics
We enrolled 43 HIV-infected patients who were admitted to
San Francisco General Hospital with a case of suspected PcP.
Twenty-eight subjects were diagnosed with PcP based upon mi-
croscopic evaluation of IS or BAL specimens; 15 subjects were
judged to not have PcP owing to a negative microscopic evalu-
ation of BAL specimen and the absence of empiric PcP therapy
before testing. These 15 subjects also did not have a subsequent
PcP diagnosis within 6 weeks of enrollment.
Detection of Pneumocystis jirovecii in Oropharyngeal Wash
From Confirmed Cases of Pneumocystis Pneumonia
We evaluated the ability of the 2 real-time PCR assays to detect
P jirovecii in OPW from the 28 microscopically confirmed cases
of PcP. We evaluated the test characteristics of these assays both
individually as well as in combination. In addition, we evaluated
the performance of the assays on a per-sample basis because
some patients provided more than 1 OPW sample. The test
characteristics of the assays are summarized in Table 1. The
combination of 2 assays increased the specificity of a diagnosis
of active PcP (100%), but sensitivity was only 74%, leading to a
high positive-predictive value and low negative-predictive value.
Individually, both the dhps and MSG real-time PCR assays de-
tected over 80% of infections among confirmed cases of PcP,
each with a positive-predictive value of >90%. In total, 45
OPW samples (of 61 total samples) from confirmed PcP
cases were detected by both assays and 12 samples were only
detected by 1 of the assays. Four samples from confirmed
cases were negative by both PCR assays.
Detection of Pneumocystis jirovecii in Oropharyngeal Wash
From Pneumocystis Pneumonia-Negative Cases
In total, 16 OPW samples were collected from PcP-negative
cases. Both PCR assays detected P jirovecii DNA in OPW wash-
es from these patients with 33% of samples positive by the dhps
PCR assay and 17% of samples positive by the MSG PCR assay
(Table 1). No samples from PcP-negative patients tested
Table 1. Test Characteristics for OPW PCR Assays Compared
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a PCR test was considered positive if it occurred in any OPW sample from the
patient.
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positive in both assays. The overall concentration of P jirovecii
DNA found in these samples (PCR positive/PCP negative) by
dhps real-time PCR tended to be lower than the concentration
in samples from infected individuals (PCR positive/BAL or IS
positive) (Figure 1).
Impact of Antibiotic Use of Detection of Pneumocystis jirovecii
by Polymerase Chain Reaction
The complete antibiotic history was available for 36 of the 43
(84%) patients in the study. We assessed the impact of the in-
terval since starting an anti-Pneumocystis medication (trimeth-
oprim-sulfamethoxazole, atovaquone, or clindamycin plus
primaquine) on the likelihood of testing positive by both PCR
tests. Among patients with microscopy-confirmed PcP, OPW
samples that were collected closer to the initiation of therapy
were more likely to be positive by both assays; the average
time of collection for both assays being positive was 4.5 days
compared with a single test being positive of 8.3 days (P = .03;
2-sided t test). This supports previous work showing that previ-
ous treatment affects the likelihood of testing P jirovecii positive
in OPWs [26]. We also assessed the correlation of P jirovecii
concentration in these samples to the time therapy and found
little correlation (R2 = 0.094; data not shown). This is likely
partly due to the large variation in P jirovecii concentrations
among samples early in the course of testing and potential var-
iation in shedding of organisms into the oropharynx.
Performance of Microsatellite Genotyping in Oropharyngeal
Wash
In total, 45 of 77 samples met our predefined definition for gen-
otyping for presumed cases (ie, both real-time PCR assays were
positive and contained ≥2 copies of P jirovecii per microliter of
extracted DNA). This concentration cutoff was decided based
upon the decreasing ability to generate a full complement of
MS alleles at lower concentrations (data not shown). This ap-
proach allowed for generation of complete or nearly complete
multilocus MS genotypes for the majority of samples, with
94% of samples having at least 5 informative MSs (Supplemen-
tary Table 2). There was some variation in the success rate for
the 6 different MS targets, with MS6 and MS8 having the lowest
success rates.
In addition to these samples, we genotyped the 19 OPW sam-
ples that tested positive for P jirovecii by only 1 real-time PCR
assay (7 samples that were MSG positive and 12 samples that
were dhps positive). After unblinding, these samples represented
12 samples from individuals who were BAL positive and 7
samples from individuals who were BAL negative and likely
colonized. We were able to generate allele sizes for 4 or more
MS in 10 of 12 (83%) and 7 of 7 (100%) of those samples,
respectively.
Microsatellite Genotyping of Longitudinal Oropharyngeal Wash
Samples
Among the 45 samples that met our predefined genotyping cri-
teria and were able to be genotyped, we had 10 individuals who
had multiple samples that all had ≥5 MS successfully geno-
typed. The range of samples genotyped from a single individual
was from 2 to 8 samples. All 10 of these infections were poly-
clonal, with at least 1 MS generating 2 alleles. Figure 2 shows
genotyping results from 2 of these individuals. In Figure 2A,
the genotyping results from a patient with 2 samples are
shown. There is a striking consistency in the allele sizes detected
between the serial samples, similar to our previous findings
when we compared 2 samples taken from a single BAL [1]. In
this sample, the dominant peak in each MS stays stable over the
course of sampling (circles in each plot), suggesting the domi-
nant clone remains stable over the sampling period. In
Figure 2B, the genotypes from longitudinal samples over a 16-
day period are seen. Although there is an overall consistency of
the alleles detected through the period, the dominant peak often
changes over time (see MS1). In addition, new alleles appear in
the sample at different time points. In most cases, that allele is
found in more than 1 sample. However, in MS7 and MS8, novel
alleles appear at certain time points. Overall, 9 of the 10 samples
showed patterns similar to Figure 2A with 4 or 5 MSs having
complete data showing a high level of reproducibility.
We used a predefined set of analysis parameters, in parti-
cular related to fluorescence intensity thresholds for calling
alleles and methods for rounding alleles into repeat sizes. The
Figure 1. Concentration of Pneumocystis jirovecii in the extracted DNA
from oropharyngeal washes (OPWs) of colonized (polymerase chain reac-
tion [PCR] positive/bronchoalveolar lavage [BAL] or induced sputum [IS]
negative) versus infected (PCR positive/BAL or IS positive) samples. The
figure shows a box and whiskers plot of the concentration of P jirovecii
in the extracted DNA from colonized and infected individuals as deter-
mined by the dhps real-time PCR. The box represents the 25th to 75th per-
centile, and the whiskers represent the minimum and maximum values
(t test; P > .05). The major surface glycoprotein PCR data were not analyzed
in a similar fashion because there were insufficient numbers of PCR-
positive samples in colonized patients, and no standard curve was included
in the PCR to allow for accurate quantification.
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assumptions used in these parameters can impact the genotyp-
ing results. First, the sensitivity of the MS method for lower fre-
quency variants is dependent on the fluorescence intensity
threshold used for calling alleles. Because the MS genotyping
method used an a priori-determined cutoff that discounted
peaks less than 33% the height of the largest peak, variants
could have been lost due to this definition. Re-evaluation of dis-
cordant MS results in the longitudinal samples showed peaks
ranging between 10% and 33% the height of the dominant
peak that would improve the repeatability of the measured geno-
type (Figure 3). Second, rounding differences can cause small
variation in the detected allele sizes. For example, in MS1 of
Figure 2B, the samples contained genotypes that were classified
as either 5 or 6 repeats. Upon hand curation of the data, these
alleles differed by less than a repeat size and likely represent
the same allele. Hand curation of allele size is laborious, but it
may be necessary for refining genotyping results for transmission
analysis.
DISCUSSION
We show that the specificity of diagnosis of PcP increases when
OPW samples test positive by 2 PCRs. This is likely because
concentrations of organisms were higher in samples from pa-
tients with pneumonia, as has been seen previously [26]. How-
ever, requiring 2 assays to be positive to define a positive test
decreased the sensitivity of detecting pneumonia. Among the
19 samples that were positive by 1 real-time PCR assay, 12
(63%) were from patients with confirmed PcP. Another limita-
tion is that in resource limited-settings, the costs associated with
multiple nucleic acid tests for diagnosis of PCP may be
prohibitive.
The detection of colonization in symptomatic patients re-
mains problematic. We used samples from symptomatic indi-
viduals in this study that had undergone more invasive testing
to allow us a gold standard with which to compare OPW PCR
results. We did not assess asymptomatic individuals. Although
Figure 2. Longitudinal analysis of microsatellites (MSs) from oropharyngeal washes (OPWs) from individual patients. The MS genotypes from longitu-
dinal OPW samples collected from individuals are shown. Within A and B, each subpanel represents data about allele sizes detected from 1 MS. The x-axis
shows the day of collection during the illness. The y-axis shows the repeat size of the detected alleles. On a given day, each MS can have more than 1 allele
detected, representing polyclonal samples. The MS repeat size of the majority allele (largest peak detected) is shown by the red circle. The MS repeat size
of minor alleles are shown with blue squares or triangles. A, A relatively simple pattern over a 2-day period in which genotypes are regularly repeated
between samples. B, Genotypes from 7 samples collected over a 16-day period. Both infections are polyclonal with at least 3 clones in the infections.
However, B shows the dynamic nature of allele genotyping based on timing of sampling.
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the mean concentration of P jirovecii was statistically different
between groups (Figure 1), the range clearly overlapped. The av-
erage concentration from the 5 colonized patients detected by
the dhps assay (3.5 copies/µL of extract) was similar to the con-
centration of the 7 samples from BAL-positive patients detected
with only the dhps assay (3.2 copies/µL). Due to the incomplete
nature of treatment data, we cannot be certain whether this
result is due to therapy, because treatment data are available
for only 2 of 5 of the colonized individuals. However, 5 of 7
of the BAL samples were collected more than 10 days after
therapy. Across all samples in the study, the samples from
BAL-positive patients that were collected later in therapy were
less likely to be positive by both assays. This finding supports
previous results suggesting that time on therapy is critical
when interpreting OPW molecular results [26]. Amongst all
samples in the study known to be collected during the first 3
days of therapy, the average concentration of P jirovecii was
180 copies/µL. Thus, it appears that OPW samples taken at ini-
tial presentation of respiratory disease, prior to any antimicro-
bial therapy, are critical for adequate diagnosis of PcP and may
have confounded our ability to diagnose colonization using
organism concentration in these symptomatic individuals.
Because OPW samples can be used to detect the vast majority
of people with Pjirovecii infection or colonization, this specimen
type might be appropriate for conducting molecular epidemiol-
ogy studies. In particular, molecular epidemiology studies are
critical for understanding the transmission dynamics of P jiro-
vecii infections, for understanding the biology of the organism,
and for designing prevention and control strategies. It is clear
that colonized infants and adults are reservoirs for P jirovecii
in the environment [27]. However, at this time, there is no
molecular evidence that these reservoirs are an important
source of P jirovecii transmission. Future studies of P jirovecii
transmission between immunocompetent hosts and immuno-
compromised patients may identify strategies to prevent PcP
in high-risk groups [1]. The MS genotyping array was able to
generate a complete or nearly complete complement (≥4) of
alleles successfully genotyped for both infected and colonized
individuals in the study. These complete multilocus genotypes
are critical for robust molecular epidemiology studies.
Individuals may harbor more than 1 strain of P jirovecii in the
lungs, and this polyclonality may compromise molecular epide-
miologic studies. The assessment of genotypes from serial sam-
ples from 1 individual can provide a sense of any dynamic
changes in prevalent strains in an infection that may confound
epidemiologic studies. Overall, the MS genotypes were repro-
ducible across serial OPW samples with 9 of 10 individuals hav-
ing patterns similar to Figure 2A, where dominant genotypes
persist through follow-up. However, in 1 patient, we saw signifi-
cant variation in alleles over time (Figure 2B). In a case in which
variations in the relative frequencies of genotypes at each MS
are observed, several factors could potentially impact the geno-
typing results. Variation occurs in the relative abundance of
each strain due to individual strains being controlled differently
over time in the host (by immunity or drug therapy), thus al-
lowing for 1 strain to vary in relative frequency in the lung
over time. Potentially, there are differences in the proportion
of each strain that could be coughed up into the oropharynx,
introducing sampling bias. In addition, technical limitations
can introduce variation. At low concentrations of input DNA,
variation in the proportion of each strain placed into each
PCR reaction to generate fragments may introduce variation
or over-amplification of specific templates, often called “jack-
potting,” which can impact alleles detected. Amplification effi-
ciency may impact the number of alleles detected in a sample:
lower efficiency PCRs, such as MS6 and MS8, often have lower
dominant peaks in the sample, making it more difficult to de-
tect minority peaks. Lastly, the mutational rate of MS in P jir-
ovecii is unknown. The instability of these MSs may complicate
transmission studies if evolution occurs within an individual
over time. We describe stability over relatively short periods
in 9 patients (average, 1.4 days; range, 1–3). Beyond this, we
Figure 3. Impact of changing peak calling threshold. A, The microsatel-
lite (MS) genotyping profile for a MS longitudinally in 1 patient using 33%
height of the dominant allele as the cutoff for allele calling (the color
scheme is the same as in Figure 2). B, The same information with addition-
al minor peaks being called (green circles) using a 10% height cutoff.
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see some variation that may represent either technical issues
noted above or within host changes. However, MSs have a
strong track record for use in molecular epidemiology studies
for multiple organisms and have been used to look at longitu-
dinal changes within mocked infections [28].
Overall, the MS array provided reproducible genotypes
among longitudinal OPW samples in the short term, but it
has several limitations. Some of these limitations, such as
rounding issues and peak fluorescence cutoffs, can easily be
modified to improve genotyping reliability. However, some of
these limitations, such as low input amounts of organisms
from OPW samples, are more difficult. The MS array provides
an initial tool for studying transmission networks. However, al-
ternate techniques, such as amplicon deep sequencing of hyper-
variable genes or enrichment of P jirovecii DNA in samples by
hybrid selection, should also be investigated. In addition, this
study does not address how genotype results from OPW sam-
ples correlate with genotypes from lower respiratory samples.
CONCLUSIONS
Pneumocystis jirovecii remains an important pathogen that still
causes significant morbidity and mortality in immunocompro-
mised patients. Molecular epidemiology studies could provide
critical insight concerning the transmission of the organism,
providing insight that could impact control and treatment ef-
forts. The role of P jirovecii colonization of immunocompetent
individuals in this transmission network remains unclear. This
project represents the first steps in developing the molecular
tools to try to define these transmission networks.
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